Carteolol hydrochloride

A non-selective beta blocker used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.Other Indication Approved (In Vitro) :Carteolol HCl is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol hydrochloride at 1 mmol/L (P<0.05) significantly inhibited H2O2-induced cell damage and was able to scavenge O2 (EC50 value: 48 mmol/L) . carteolol hydrochloride has a protective action against UVB-induced HCEC damage, and its radical scavenging ability may be an important basis for this effect . The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety. This efficacy wasy was verified at 9 AM (24 hours after the last drop of long-acting carteolol or 12 hours after that of standard carteolol) and at 11 AM (2 hours after the morning drop) . The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment.

51781-21-6

NSC 300906 | OPC 1085

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 13.33 mg/mL

CC (C) (C) NCC (COC1=CC=CC2=C1CCC (=O) N2) O.Cl

C16H25ClN2O3

328.8343

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.